Apr 10 |
89bio signs deal for construction of a production facility in China
|
Apr 3 |
89bio Inc CEO Rohan Palekar Sells 52,718 Shares
|
Mar 27 |
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
|
Mar 18 |
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
|
Mar 13 |
13 Best Biotech Stocks To Buy Under $20
|
Mar 12 |
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
|
Mar 8 |
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 7 |
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
|
Mar 5 |
89bio to Participate in the Leerink Partners Global Biopharma Conference
|
Mar 5 |
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
|